Although there was a consistent trend for estimates of relative treatment effects in favor of IFN β-1a 44 μg SC tiw compared with placebo across all other patient subgroups, it did not reach statistical significance.
← all excerpts
Effect of interferon beta-1a subcutaneously three times weekly on clinical and radiological measures and no evidence of disease activity status in patients with relapsing-remitting multiple sclerosis at year 1.
1
—
—